New FDA draft guidance suggests the inclusion of patients with HIV, hepatitis B and hepatitis C in cancer clinical trials based on predetermined conditions. The guidelines are being revised because too tightly defined criteria deter patient recruitment, which affects all other factors of a drug testing trial, including publication of data.
FDA releases draft guidance on eligibility criteria for cancer trials
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.